Technical Analysis for ALNY - Alnylam Pharmaceuticals, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
180 Bearish Setup | Bearish Swing Setup | 0.00% | |
Multiple of Ten Bearish | Other | 0.00% | |
Gapped Up | Strength | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Multiple of Ten Bearish | Other | -1.25% | |
Outside Day | Range Expansion | -1.25% | |
Up 3 Days in a Row | Strength | -1.25% | |
Oversold Stochastic | Weakness | -1.25% | |
Oversold Stochastic | Weakness | -0.75% | |
Multiple of Ten Bearish | Other | -0.68% |
Alert | Time |
---|---|
60 Minute Opening Range Breakdown | about 12 hours ago |
Down 1% | about 12 hours ago |
10 DMA Support | about 13 hours ago |
Rose Above Previous Day's High | about 13 hours ago |
Up 1% | about 13 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/02/2024
Alnylam Pharmaceuticals, Inc. Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing novel therapeutics based on RNA interference (RNAi). Its principal programs under clinical or pre-clinical development include ALN-TTR comprising ALN-TTR02 and ALN-TTRsc for the treatment of transthyretin-mediated amyloidosis; ALN-AT3 for the treatment of hemophilia and rare bleeding disorders; ALN-AS1 for the treatment of acute intermittent porphyria; ALN-PCS for the treatment of hypercholesterolemia; and ALN-TMP for the treatment of hemoglobinopathies, including beta-thalassemia. The company's early stage program comprise ALN-AAT, an RNAi therapeutic targeting the mutant Z-allele in alpha-1-antitrypsin deficiency (AAT deficiency) for the treatment of AAT deficiency-associated liver disease. It also has two partner-based programs in clinical development, including ALN-RSV01 for the treatment of respiratory syncytial virus infection; and ALN-VSP for the treatment of liver cancers, as well as one candidate in pre-clinical development comprising ALN-HTT for the treatment of Huntington's disease. The company has strategic alliances with F. Hoffmann-La Roche Ltd; Arrowhead Research Corporation; Takeda Pharmaceutical Company Limited; Monsanto Company; Isis Pharmaceuticals, Inc.; Novartis Pharma AG; Medtronic, Inc.; Kyowa Hakko Kirin Co., Ltd.; Genzyme Corporation; The Medicines Company; Cubist Pharmaceuticals, Inc; Biogen Idec Inc.; and Ascletis Pharmaceuticals (Hangzhou) Co., Ltd. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Clinical Development Cholesterol Liver Disease Amyloid Amyloidosis Hemoglobin Huntington's Disease Hemophilia Antitrypsin Deficiency Hypercholesterolemia Spinal Muscular Atrophy Genzyme Rna Interference Alnylam Pharmaceuticals Deficiency Hemophilia A Liver Cancer Thalassemia Therapeutic Gene Modulation Transthyretin Treatment Of Hemophilia Hemoglobinopathies Medtronic Acute Intermittent Porphyria Alpha 1 Antitrypsin Deficiency Beta Thalassemia Monsanto
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 218.88 |
52 Week Low | 143.52 |
Average Volume | 922,953 |
200-Day Moving Average | 179.05 |
50-Day Moving Average | 168.01 |
20-Day Moving Average | 151.99 |
10-Day Moving Average | 148.83 |
Average True Range | 4.84 |
RSI (14) | 35.06 |
ADX | 33.19 |
+DI | 15.28 |
-DI | 25.06 |
Chandelier Exit (Long, 3 ATRs) | 149.50 |
Chandelier Exit (Short, 3 ATRs) | 158.04 |
Upper Bollinger Bands | 160.73 |
Lower Bollinger Band | 143.26 |
Percent B (%b) | 0.24 |
BandWidth | 11.49 |
MACD Line | -5.22 |
MACD Signal Line | -5.85 |
MACD Histogram | 0.6326 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 153.14 | ||||
Resistance 3 (R3) | 153.70 | 152.35 | 152.19 | ||
Resistance 2 (R2) | 152.35 | 150.89 | 152.07 | 151.87 | |
Resistance 1 (R1) | 149.88 | 149.99 | 149.21 | 149.32 | 151.55 |
Pivot Point | 148.53 | 148.53 | 148.19 | 148.25 | 148.53 |
Support 1 (S1) | 146.06 | 147.07 | 145.39 | 145.50 | 143.27 |
Support 2 (S2) | 144.71 | 146.17 | 144.43 | 142.95 | |
Support 3 (S3) | 142.24 | 144.71 | 142.64 | ||
Support 4 (S4) | 141.68 |